ClinicalTrials.gg
CompletedNCT06579053Updated Aug 30, 2024

Bioequivalence Study of Spironolactone Tablets in Healthy Subjects

A Phase 1 interventional study of Spironolactone Tablets (Test) and Spironolactone Tablets (Reference) in Bioequivalence Study, sponsored by SPH Sine Pharmaceutical Laboratories Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-30.

Sponsored by SPH Sine Pharmaceutical Laboratories Co., Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Mar 2023, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The goal of this clinical trial is to Evaluate the Bioequivalence of Spironolactone Tablets 100mg (by SPH Sine Pharmaceutical Laboratories Co.,Ltd) and ALDACTONE® tablets 100mg (by GD SEARLE LLC) in Chinese Healthy Adult Volunteers under Fasting and Fed Conditions. It will also learn about the safety of the two drugs.

02

Conditions studied

  • Bioequivalence Study
03

In context

Lead sponsor

SPH Sine Pharmaceutical Laboratories Co., Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old ≤ age ≤ 40 years old, male or female;
  2. Weight: ≥ 50 kg for male and ≥ 45 kg for female; (BMI) in the range of 19-26 kg/m2 (including 19 and 26);
  3. No history of heart, liver, kidney, gastrointestinal, nervous system, mental abnormalities and metabolic abnormalities, no history of allergy to agents, no history of serious infections and serious injuries, etc;
  4. Physical examination, vital signs examination, examination, and laboratory examination of important indicators are normal or within the range considered acceptable by the sponsor/investigator;
  5. No parenting plan and access to reliable during the trial and within 3 months of the last dose;
  6. Fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial and sign the ICF, and be able to complete the entire trial process according to the trial requirements.

Exclusion criteria

Exclusion Criteria:

  1. Persons with a known history of allergy, allergic disorder or to the test product and any of its components or related agents;
  2. Persons with a clear history of central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematological system, metabolic disorders (e.g. hyperkalemia) or other diseases that are not suitable for participation in clinical trials (e.g. history of psychiatric disorders, etc.);
  3. Those who have donated blood or lost ≥ 400 mL of blood within 3 months prior to enrollment;
  4. Those who have taken any medication within 2 weeks prior to screening;
  5. Those who have participated in other drug clinical trials within 3 months prior to enrollment;
  6. current or former drug abuser or alcohol addict who consumes alcohol at least 2 times a day or 14 or more times a week, or is an avid drinker (1 drink defined as 125 mL of wine, 220 mL of beer or 50 mL of liquor; alcoholism defined as 5 or more drinks in approximately 2 hours);
  7. Those who smoked more than 10 cigarettes per day during the 3 months prior to screening;
  8. surface antigen (HBsAg), antibodies, syphilis spirochete antibodies and antibody-positive persons;
  9. Those with positive drug abuse screening results or alcohol breath test results;
  10. Those with positive pregnancy test results(female);
  11. Those who have other factors that the investigator considers unsuitable for participation in the trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Test product

    Spironolactone Tablets, 100 mg/tablet, to be orally administered.

    Drug: Spironolactone Tablets (Test)

  • Active comparator
    Reference product

    ALDACTONE® Tablets,100 mg/tablet, to be orally administered.

    Drug: Spironolactone Tablets (Reference)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum Observed Concentration in Plasma

    Time frame: up to 24 hours after tablet intake

  2. AUC 0-t

    Area Under the Concentration-time Curve From Time Zero to Time of Last

    Time frame: up to 24 hours after tablet intake

  3. AUC 0-∞

    Area Under the Concentration-time Curve From Time Zero to Infinity

    Time frame: up to 24 hours after tablet intake

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, Shanghai 200031, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in May 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 30, 2024
StartActual
Mar 22, 2023
Primary completionActual
May 5, 2023
CompletionActual
Aug 23, 2023
Last update
Aug 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06579053
Lead sponsor
SPH Sine Pharmaceutical Laboratories Co., Ltd.
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Mar 22, 2023
Primary completion
May 5, 2023
Completion
Aug 23, 2023
Last update
Aug 30, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Spironolactone

Other studies from this sponsor

SPH Sine Pharmaceutical Laboratories Co., Ltd.

Start the discussion